2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Blood Banking, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Women’s Health, Workforce, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Thromboembolism, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Paroxysmal Nocturnal Hemoglobinuria, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric
PAPER

2572 LLM-automated deauville score extraction from serial PET/CT reports reproduces overall survival stratification after CAR T-cell therapy for B-cell lymphoma

Janamejey Gaur, MD, Vaishali Gautam, BS2, Chunyi Zhang3, James P Long, PhD4, Benjamin Mescher5, Sattva S Neelapu Sr, MD6, Sairah Ahmed, MD7, Anath Christopher Lionel, MD, PhD8, Swaminathan P. Iyer, MD9
1 UT MD Anderson Cancer Center, Houston, Texas, United States
2 UT MD Anderson Cancer Center, Houston, Texas, United States
3 UT MD Anderson Cancer Center, Houston, Texas, United States
4 UT MD Anderson Cancer Center, Houston, Texas, United States
5 UT MD Anderson Cancer Center, Houston, Texas, United States
6 UT MD Anderson Cancer Center, Houston, Texas, United States
7 UT MD Anderson Cancer Center, Houston, Texas, United States
8 UT MD Anderson Cancer Center, Houston, Texas, United States
9 UT MD Anderson Cancer Center, Houston, Texas, United States

Background: PET/CT using the Deauville 5-point scale (DS) is the standard for response assessment after CAR T-cell therapy for B-cell lymphomas. However, extracting serial scores and reconciling radiology reports with clinical interpretations require labor-intensive chart review. We evaluated a large language model (LLM)-driven pipeline for automated DS extraction and interpretation, testing whether the resulting response classifications reproduced the expected association between early metabolic response and overall survival (OS).

Methods: This IRB-approved retrospective study used de-identified data under a consent waiver. We analyzed 744 consecutive patients with aggressive B-cell lymphomas who received standard-of-care CAR T-cell therapy at a tertiary center, encompassing 1,841 PET/CT reports at baseline (n=713) and on days 30 (n=687), 60 (n=48), and 90 (n=393). Clinical and imaging data were retrieved using Context Engine, preserving data provenance from the electronic health record. A multi-model pipeline (GPT-4o, Gemini 2.0, and Claude 3.5 Haiku) processed PET reports by extracting an explicitly stated DS or, when absent, by interpreting FDG-uptake descriptions. Clinical oncology notes were independently processed to capture physician assessments, addenda, supplemental imaging, and revised interpretations. Concordance between PET-only LLM-derived scores (L-scores) and clinical-contextualized scores (C-scores) was the primary outcome. Post-infusion scores were operationally classified as complete metabolic response (CMR; DS 1–3), partial response (PR; DS 4), or progressive disease (PD; DS 5). OS was analyzed using Kaplan-Meier, log-rank, and multivariable Cox regression from day-30 and day-90 scan-date landmarks.

Results: Among 1,495 reports with both L- and C-scores, exact agreement was 93.5% (1,398/1,495; κ=0.914), and 97.9% agreed within +/- 1 DS point. Among 158 paired reports without an explicitly stated DS, for which the L-score was inferred from FDG uptake descriptions, 133 (84.2%) matched exactly and 92.4% agreed within +/- 1 point. Of the 97 discordant reports, 38 (39.2%) involved the adjacent DS 4/5 boundary - the largest discordance category. Contributing factors included physician reinterpretation, non-lymphoma FDG uptake, and addenda issued after the original report. CMR rates were 65.8% at day 30 and 63.6% at day 90. Among 379 patients with baseline DS5 and an evaluable day-30 assessment, 220 (58.0%) achieved CMR. In the day-30 landmark analysis (n=637; 267 deaths), median OS was 62.9 months for CMR, 19.5 months for PR, and 4.9 months for PD (log-rank p<0.0001). At the day-90 landmark (n=355; 130 deaths), median OS was 78.7, 23.9, and 9.7 months, respectively (log-rank p<0.0001). In a multivariable day-30 model adjusted for baseline DS, PD (HR 3.81, 95% CI 2.80–5.18; p<0.001) and PR (HR 1.84, 95% CI 1.31–2.58; p<0.001) independently predicted mortality, while baseline DS5 retained modest prognostic significance (HR 1.60, 95% CI 1.05–2.46; p=0.029). Among 320 patients with both baseline and day-90 scores, day-90 PD (HR 4.34, 95% CI 2.86–6.60; p<0.001) and PR (HR 2.57, 95% CI 1.40–4.71; p=0.002) remained prognostic, whereas baseline DS5 did not (HR 1.35, 95% CI 0.71–2.58; p=0.36).

Conclusion: LLM-derived early metabolic response strongly stratified OS after CAR T-cell therapy, with day-30 PD conferring a nearly four-fold adjusted mortality hazard relative to CMR. By day 90, metabolic response remained a strong prognostic factor and largely superseded the prognostic contribution of baseline DS. The pipeline also demonstrated high concordance between PET-only L-scores and clinical-contextualized C-scores. However, clinical note context remained important for resolving reports without an explicit DS and for addressing disagreements at the DS 4/5 boundary. These findings support automated Deauville score extraction as a scalable approach for response assessment and survival stratification. Limitations include the absence of an image-adjudicated gold standard, reliance on the C-score as the comparator, sparse day-60 sampling, and an untested proportional hazards assumption. Adjudicated validation and incorporation of treatment history are ongoing and will be presented at the ASH Annual Meeting.

Janamejey Gaur, MD: No relevant conflicts of interest to declare.